AllianceBernstein
IPSC icon

AllianceBernstein’s Century Therapeutics IPSC Stock Holding History

AllianceBernstein’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,020
Closed -$9.53K – 3275
2025
Q1 		$9.53K Hold
20,020
– – ﹤0.01% 3193
2024
Q4 		$20.2K Hold
20,020
– – ﹤0.01% 3211
2024
Q3 		$34.2K Hold
20,020
– – ﹤0.01% 3207
2024
Q2 		$51.1K Buy
20,020
+8,440
+73% +$26.7K ﹤0.01% 3184
2024
Q1 		$48.4K Hold
11,580
– – ﹤0.01% 3093
2023
Q4 		$38.4K Sell
11,580
-1,100
-9% -$2K ﹤0.01% 3149
2023
Q3 		$25.4K Hold
12,680
– – ﹤0.01% 3166
2023
Q2 		$40.1K Buy
12,680
+1,880
+17% +$6.06K ﹤0.01% 3141
2023
Q1 		$37.5K Buy
+10,800
New +$47.4K ﹤0.01% 3109

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's IPSC Position: Q2 2025 in Review

AllianceBernstein sold out of Century Therapeutics (IPSC) in Q2 2025, closing a stake of 20,020 shares — an estimated $9.53K sold.

AllianceBernstein first reported a position in IPSC in Q1 2023 and held it in 9 quarters. The position peaked at $51.1K in Q2 2024. 65 funds tracked by Wall St. Rank hold IPSC as of Q2 2025.

  • AllianceBernstein reported no remaining Century Therapeutics position as of Q2 2025 after selling out during the quarter.
  • AllianceBernstein sold 20,020 Century Therapeutics shares in Q2 2025, an estimated $9.53K.
  • AllianceBernstein first reported a position in Century Therapeutics in Q1 2023 and held it in 9 quarters.
  • AllianceBernstein's Century Therapeutics position peaked at $51.1K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.